Glenveigh Medical
http://glenveigh.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Glenveigh Medical
Radionuclide Therapy Developers Attract Investor Attention in March China Fundraising
China's Chengdu New Radiomedicine Technology and the radiotherapy CRDMO Mitro Biotech bagged a combined $94m in their respective new financing rounds during March. Meanwhile, Beijing Varnotech Biopharm secured $83m for its vaccine candidates for the prevention of herpes zoster and respiratory syncytial virus infections.
The Biopharma A List: Taking The Pulse Of Newco Creation
On the new company creation front, using Series A financings as a proxy, start-ups have not escaped the challenging funding environment. Here we update trends in those first-time rounds for 2023.
Finance Watch: Q4 Venture Financings Slumped But 2024 Outlook Is Optimistic
Private Company Financings: Year-end data from Pitchbook/NVCA, like recent Evaluate numbers, show venture fundraising slid from the third to fourth quarters. However, Taiho increased its VC fund by $100m, Ji Xing closed a $162m series D round and MAPS raised more than $100m.
The New Antibodies Revolutionizing Medicine
Nucleic acid-based therapies are poised to revolutionize medicine – just as antibodies did thirty years ago.
Company Information
- Industry
- In Vitro Diagnostics
- Pharmaceuticals
-
Medical Devices
-
Surgical Equipment & Devices
- Minimally or Less Invasive
-
Surgical Equipment & Devices
- Other Names / Subsidiaries
-
- Glenveigh Pharmaceuticals, LLC
- Glenveigh Surgical
- Glenveigh Research
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice